YCSND demonstrated excellent anti-inflammatory effects against ALI by reducing the mRNA levels of the pro-inflammatory factors Il6, Il1β, Tnfα and the upstream inflammatory regulator Nfκb1 (Figures 7A–D). This evidence concerns the gene IL6 and acute respiratory distress syndrome.